Shanghai, China is making every effort to build the world's top biomedical industry cluster. The Action Plan for Promoting High Quality Development of Shanghai Biomedical Industry (2018-2020) was officially released. By 2020, the scale of Shanghai’s biomedical industry is expected to reach 400 billion RMB, with more than 50 listed drugs declared.

To cope with the opportunities and challenges brought by the integration of Shanghai's biopharmaceutical industry and the construction of Shanghai Technology Innovation Center, the China Bio-Pharm Partnering Forum 2019 (BIO-PHARM2019) will be held in Shanghai, China from September 26 to 27. 400+ domestic and foreign biopharm innovative enterprises and guests from upstream and downstream enterprises and investors will be gathered in Shanghai and serve as a platform for industrial experts to communicate and dig cooperation opportunities, so as to explore the way for the future development of Shanghai biopharma industry.

Organization

Organizer

Co-Organizer
Supporter

Agenda Framework

--- AGENDA-AT-A-GLANCE ---

PLENARY SESSION
Sep. 26 AM

R&D AND COOPERATION ON BIOLOGICAL MEDICINE
Sep. 26 PM

INNOVATIVE BIOTECHNOLOGY FORESIGHT

Hot Topics
✓ Interpretation of Action Plan for Promoting High Quality Development of Shanghai Biomedical Industry

Shanghai Science and Technology Commission
✓ Dorzagliatin: The R&D of New Generation of Type 2 Diabetes Medicines

ZHANG Yi, SVP, Clinical R&D, Hua Medicine

✓ Research and Industrialization of New Drugs

FU Lijie, Academician of the American Academy of Toxicology, National Shanghai Center for New Drug Safety Evaluation and Research

✓ The Latest Research Progress and Technical Breakthrough of the New Generation of "Oncolytic Virus Therapeutics"

Grace Zhou, Founder and CEO, Immvira

✓ Starting from China, Globally Oriented: The First Unique Innovation Drug Model

LUO Wen, Chief Executive Officer, Chief Scientific Officer, Denovo Biopharma

✓ Development and Future Layout of Bispecific Antibodies

Bin PENG, CMO, EpimAb Biotherapeutics

✓ Developing Life-changing Drugs for Patients Based on Innovation and Cooperation

Feng Bian, Senior Director, Asia Emerging Science Lead (Shanghai), Asia Discovery Labs (ADL), Emerging Science & Innovation (ES&I), Pfizer Worldwide R&D

✓ A Preliminary Study on the Current Situation and Strategies of NASH New Drugs
ZHOU Zhou, Director of Pharmacology and Scientific Affairs, Terns China Biotechnology Co., Ltd.

✓ Transgenic Mouse Platforms Generating Fully Human Monoclonal Antibodies Assist the Development of Innovative Tumor Immunotherapy

ZHOU Sixiang, Senior Director Asia Pacific, Harbour BioMed

✓ Discovery of Small Molecular Innovative Drugs

LU Xianping, Chairman & General Manager, Chipscreen Biosciences

✓ Dendritic Cell Therapy Based on SEA-MAP Load

LUO Jin, General Manager, Antae Biogene

More information, please visit our website: [http://www.bio-pharmchina.com/](http://www.bio-pharmchina.com/)

**Registration Fee**

Delegate: $ 600/ person
Roadshow: $ 2,000/ company

1/ Registration fee includes luncheon, document, coffee breaks, excludes hotel accommodation
2/ 3 delegates or more as Group Registration can enjoy 20 percent off
3/ 2,000USD for Roadshow includes 20-minutes-presentation, 2 tickets and Simultaneous Interpretation services

**Sponsor Opportunity**

Only 2 Booths and 1 Speech Chance are available now!
Contact Information

Sponsor Opportunity
Mr. Daniel Xiao
Tel.: +86-139-1746-5409
Email: danielxiao@healife.com

Registration/Media Contact
Ms. Annie Xu
Tel.: +86-186-2165-4360
Email: anniexu@healife.com

Join us this September at what promises to be another successful knowledge-sharing forum in Shanghai, China!